Illumina Ventures
Illumina Ventures visions is to improve human health by unlocking the power of the genome.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Illumina Ventures Information
Geographic Data
Address: 499 Illinois St Ste 210
City: San Francisco
State: CA
Zip: 94158
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$555M
Social
Twitter
Linkedin
Crunchbase
Metrics
7,951,904Website Global Rank
360Website Monthly Traffic
Twitter Followers
Description
Illumina Ventures is an independently managed venture fund in a strategic partnership with Illumina. Illumina provides the majority of their capital and access to the expertise and vision of the world&s;s leading genomics solutions provider. They invest primarily in early stage companies, in areas where their expertise and special relationship with Illumina can add value. They typically syndicate with other leading institutional and strategic investors. Focus areas include applications of genomics in life science research, healthcare, agriculture and environmental science, public safety and personal wellness.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 10/2015 | 23andMe | Series E | 115M |
| 12/2022 | Protillion Biosciences | Series A | 0 |
| 11/2017 | NanoCellect Biomedical | Series B | 0 |
| 3/2018 | Cernostics | Series A | 2.5M |
| 12/2018 | Kallyope | Series B | 21M |
| 5/2017 | Genome Medical | Series A | 0 |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 8/2021 | NanoCellect Biomedical | Series D | 0 |
| 9/2021 | Walking Fish Therapeutics | Series A | 50M |
| 5/2018 | LunaDNA | Venture Round | 0 |
| 5/2019 | DNA Script | Series B | 38.5M |
| 6/2017 | Serimmune | Series A | 8M |
| 1/2018 | NanoCellect Biomedical | Venture Round | 250k |
| 1/2018 | Genome Medical | Series A | 11M |
| 11/2018 | Stilla Technologies | Series A | 18.3M |
| 5/2019 | LunaDNA | Venture Round | 4.6M |
| 9/2021 | Alamar Biosciences | Series B | 80M |
| 2/2021 | NanoCellect Biomedical | Series C | 0 |
| 4/2023 | Pattern Bioscience | Series D | 0 |
| 9/2022 | LetsGetChecked | Series D | 0 |
| 3/2022 | Sherlock Biosciences | Series B | 0 |
| 5/2020 | LetsGetChecked | Series C | 71M |
| 7/2020 | DNA Script | Series B | 50M |
| 12/2015 | Kallyope | Series A | 44M |
| 7/2019 | Cradle Genomics | Series A | 0 |
| 4/2023 | Pattern Bioscience | Series C | 0 |
| 3/2020 | Kallyope | Series C | 112M |
| 1/2020 | Fluent BioSciences | Series A | 0 |
| 12/2017 | LunaDNA | Seed Round | 2M |
| 4/2016 | Human Longevity | Series B | 220M |
| 9/2017 | DNA Script | Series A | 13.2M |
| 7/2020 | Pattern Bioscience | Series B | 9M |
| 2/2020 | Stilla Technologies | Series B | 0 |
| 12/2022 | SonoThera | Series A | 0 |
| 10/2021 | RedShift BioAnalytics | Series E | 20M |
| 10/2021 | DNA Script | Series C | 0 |
| 8/2019 | Delfi Diagnostics | Seed Round | 5.5M |
| 11/2018 | Ribometrix | Series A | 30M |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 1/2016 | Twist Bioscience | Series D | 61M |
| 4/2020 | Actym Therapeutics, Inc. | Series A | 34M |
| 6/2021 | LetsGetChecked | Series D | 150M |
| 5/2020 | SQZ Biotech | Series D | 0 |
| 5/2019 | LunaPBC | Venture Round | 4.6M |
| 11/2021 | Stilla Technologies | Debt Financing | 0 |
| 2/2022 | Kallyope | Series D | 0 |
| 8/2021 | Genome Medical | Series C | 0 |
| 7/2020 | Encoded Therapeutics | Series D | 0 |
| 8/2018 | SQZ Biotech | Series C | 0 |
| 2/2018 | Kallyope | Series B | 66M |
| 7/2020 | Genome Medical | Series B | 0 |
| 1/2016 | Biota Technology | Venture Round | - |
| 11/2020 | Rebus Bio | Series B | 20M |
| 9/2019 | Ribometrix | Equity | 7.8M |
| 1/2021 | Delfi Diagnostics | Series A | 0 |
| 5/2023 | Pluton Biosciences | Series A | 0 |
| 1/2016 | Desktop Genetics | Venture Round | - |
| 5/2023 | Pluton Biosciences | Series A | 0 |
| 4/2023 | Pattern Bioscience | Series C | 0 |
| 12/2022 | Protillion Biosciences | Series A | 0 |
| 12/2022 | SonoThera | Series A | 0 |
| 9/2022 | LetsGetChecked | Series D | 0 |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 3/2022 | Sherlock Biosciences | Series B | 0 |
| 2/2022 | Kallyope | Series D | 0 |
| 11/2021 | Stilla Technologies | Debt Financing | 0 |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
